The endocannabinoid system and migraine

Experimental Neurology

Volumn 224, Issue 1, 2010, Pages 85-91

  Greco, Rosaria ^a,b   Gasperi, Valeria ^c,d   Maccarrone, Mauro ^d,e   Tassorelli, Cristina ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY OF TERAMO   (Italy)

Author keywords

Anandamide; Migraine; Nitroglycerin; Pain; Platelet; Vanilloid receptors

Indexed keywords

ANANDAMIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTAMIC ACID; NITRIC OXIDE; PALMIDROL; PROENKEPHALIN; PROSTAGLANDIN SYNTHASE; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; SUBSTANCE P; VANILLOID RECEPTOR 1;

ANTINOCICEPTION; ARTICLE; BRAIN STEM; CLUSTER HEADACHE; HEADACHE; HUMAN; HYPERALGESIA; HYPOTHALAMUS; MIGRAINE; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NOCICEPTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SEROTONIN RELEASE; SPINAL CORD DORSAL HORN; TRIGEMINAL NUCLEUS;

EID: 77953714712     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.03.029     Document Type: Review

References (88)

1. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007, 10:870-879.
2. Akerman S., Kaube H., Goadsby P.J. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J. Pharmacol. Exp. Ther. 2004, 309:56-63.
3. Akerman S., Kaube H., Goadsby P.J. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br. J. Pharmacol. 2004, 142:1354-1360.
4. Akerman S., Holland P.R., Goadsby P.J. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J. Pharmacol. Exp. Ther. 2007, 320:64-71.
5. Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y., Birch R., Benham C., Bountra C., Chessell I.P., Anand P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008, 138:667-680.
6. Anand P., Whiteside G., Fowler C.J., Hohmann A.G. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res. Rev. 2009, 60:255-266.
7. 1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann. Neurol. 2004, 56:371-381.
8. Battista N., Fezza F., Maccarrone M. Endocannabinoids and their involvement in the neurovascular system. Curr. Neurovasc. Res 2004, 1:129-140.
9. Bellocchio L., Cervino C., Pasquali R., Pagotto U. The endocannabinoid system and energy metabolism. J. Neuroendocrinol. 2008, 20:850-857.
10. Beltramo M. The cannabinoid system and pain: towards new drugs?. J. Soc. Biol. 2009, 203:99-106.
11. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. Cell Biol. 2003, 163:463-468.
12. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
13. Buzzi M.G., Tassorelli C., Nappi G. Peripheral and central activation of trigeminal pain pathways in migraine: data from experimental animal models. Cephalalgia 2003, 23:1-4.
14. Camp W.H. The antiquity of hemp as an economic plant. J.N.Y. Bot. Gard. 1936, 37:110-114.
15. Cheer J.F., Cadogan A.K., Marsden C.A., Fone K.C., Kendall D.A. Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 1999, 38:533-541.
16. Cupini L.M., Bari M., Battista N., Argirò G., Finazzi-Agrò A., Calabresi P., Maccarrone M. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 2006, 26:277-281.
17. Cupini L.M., Costa C., Sarchielli P., Bari M., Battista N., Eusebi P., Calabresi P., Maccarrone M. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol. Dis. 2008, 30:186-189.
18. De Vries P., Villalón C.M., Saxena P.R. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol. 1999, 375:61-74.
19. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
20. Di Marzo V., Deutsch D.G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol. Dis. 1998, 5:386-404.
21. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophys. 1995, 73:907-910.
22. Fezza F., De Simone C., Amadio D., Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell. Biochem. 2008, 49:101-132.
23. Goadsby P.J. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002, 22:107-111.
24. Greco R., Tassorelli C., Cappelletti D., Sandrini G., Nappi G. Activation of the transcription factor NF-kappaB in the nucleus trigeminalis caudalis in an animal model of migraine. Neurotoxicology 2005, 25:795-800.
25. Greco R., Gasperi V., Sandrini G., Bagetta G., Nappi G., Maccarrone M., Tassorelli C. Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat. Cephalalgia 2009, Epub ahead of print.
26. Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., Davar G., Makriyannis A., Vanderah T.W., Mata H.P., Malan T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3093-3098.
27. Juhasz G., Lazary J., Chase D., Pegg E., Downey D., Toth Z.G., Stones K., Platt H., Mekli K., Payton A., Anderson I.M., Deakin J.F., Bagdy G. Variations in the cannabinoid receptor 1 gene predispose to migraine. Neurosci. Lett. 2009, 461:116-120.
28. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
29. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14:923-930.
30. Kimura T., Ohta T., Watanabe K., Yoshimura H., Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol. Pharm. Bull. 1998, 21:224-226.
31. Knight Y. Brainstem modulation of caudal trigeminal nucleus: a model for understanding migraine biology and future drug targets. Headache Currents 2005, 2:108-118.
32. Kosersky D.S., Dewey W.L., Harris L.S. Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat. Eur. J. Pharmacol. 1973, 24:1-7.
33. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., Iacono A., Mattace Raso G., Meli R., Piomelli D., Calignano A. Modulation of neuropathic and inflammatory pain by the endocannabinoid Transport inhibitor AM404. J. Pharmacol. Exp. Ther. 2006, 317:1365-1371.
34. Lassen L.H., Ashina M., Christiansen I., Ulrich V., Grover R., Donaldson J., Olesen J. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998, 18:27-32.
35. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
36. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 2000, 275:31938-3193845.
37. Mackie K., Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006, 8:E298-E306.
38. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-668.
39. McKinney M.K., Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 2005, 74:411-432.
40. Messlinger K., Suzuki A., Pawlak M., Zehnter A., Schmidt R.F. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br. J. Pharmacol. 2000, 129:1397-1404.
41. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000, 21:1735-1742.
42. Monory K., Blaudzun H., Massa F., Kaiser N., Lemberger T., Schütz G., Wotjak C.T., Lutz B., Marsicano G. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 2007, 5:e269.
43. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43:16-20.
44. Moskowitz M.A., Buzzi M.G., Sakas D.E., Linnik M.D. Pain mechanisms underlying vascular headaches. Progress Report Rev. Neurol. 1989, 145:181-193.
45. Myers D.E. Potential neurogenic and vascular roles of nitric oxide in migraine headache and aura. Headache 1999, 39:118-124.
46. Nackley A.G., Makriyannis A., Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 119:747-757.
47. Nyholt D.R., Morley K.I., Ferreira M.A., Medland S.E., Boomsma D.I., Heath A.C., Merikangas K.R., Montgomery G.W., Martin N.G. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am. J. Hum. Genet. 2005, 77:500-512.
48. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 2004, 279:5298-5305.
49. Okamoto Y., Tsuboi K., Ueda N. Enzymatic formation of anandamide. Vitam. Horm. 2009, 81:1-24.
50. Olesen J., Thomsen L.L., Lassen L.H., Olesen I.J. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 1995, 15:94-100.
51. Osler W., McCrae T. The principles and practice of medicine 1915, Appleton and Co., New York and London, 1225.
52. Palkovits M., Harvey-White J., Liu J., Kovacs Z.S., Bobest M., Lovas G., Bagó A.G., Kunos G. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience 2008, 152:1032-1039.
53. Pernía-Andrade A.J., Kato A., Witschi R., Nyilas R., Katona I., Freund T.F., Watanabe M., Filitz J., Koppert W., Schüttler J., Ji G., Neugebauer V., Marsicano G., Lutz B., Vanegas H., Zeilhofer H.U. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 2009, 325:760-764.
54. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63:569-611.
55. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:101-121.
56. Price T.J., Helesic G., Parghi D., Hargreaves K.M., Flores C.M. The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 2003, 120:155-162.
57. Ratnam E.V. Cannabis indica. J. Brit. Med. Assoc. Ceylon Branch 1916, 13:30-34.
58. Reuter U., Chiarugi A., Bolay H., Moskowitz M.A. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann. Neurol. 2002, 51:507-516.
59. Rice A.S., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostagl. Leukot. Essent. Fatty Acids 2002, 66:243-256.
60. Robbins M.S., Tarshish S., Solomon S., Grosberg B.M. Cluster attacks responsive to recreational cannabis and dronabinol. Headache 2009, 49:914-916.
61. Rossi S., De Chiara V., Musella A., Kusayanagi H., Mataluni G., Bernardi G., Usiello A., Centonze D. Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J. Neurosci. 2008, 28:7284-7892.
62. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neur. Endocrinol. Lett. 2004, 25:31-39.
63. Sagar D.R., Gaw A.G., Okine B.N., Wong A., Woodhams S.G., Kendall D.A., Chapman V. Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol. Pain 2009, 8:5-59.
64. Sancho R., Calzado M.A., Di Marzo V., Appendino G., Muñoz E. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 2003, 63:429-438.
65. Sarchielli P., Alberti A., Floridi A., Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001, 57:132-134.
66. Sarchielli P., Alberti A., Gallai B., Coppola F., Baldi A., Gallai V. Brain-derived neurotrophic factor in cerebrospinal fluid of patients with chronic daily headache: relationship with nerve growth factor and glutamate levels. J. Headache Pain 2002, 3:129-135.
67. Sarchielli P., Pini L.A., Coppola F., Rossi C., Baldi A., Mancini M.L., Calabresi P. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 2007, 32:1384-1390.
68. Sarker K.P., Maruyama I. Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. Cell. Mol. Life Sci. 2003, 60:1200-1208.
69. Shields K.G., Goadsby P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?. Brain 2005, 128:86-97.
70. Strecker T., Dux M., Messlinger K. Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow. J. Vasc. Res. 2002, 39:489-496.
71. Sugiura T. Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Biofactors 2009, 35:88-97.
72. Szallasi A., Blumberg P.M. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev. 1999, 51:159-212.
73. Tassorelli C., Greco R., Wang D., Sandrini G., Nappi G. Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. Eur. J. Pharmacol. 2006, 534:103-107.
74. Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P., Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 2001, 21:1104-1109.
75. Tóth A., Blumberg P.M., Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam. Horm. 2009, 81:389-419.
76. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 8:393-411.
77. Tsuboi K., Takezaki N., Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem. Biodivers. 2007, 4:1914-1925.
78. Ulugöl A., Ozyigit F., Yesilyurt O., Dogrul A. The additive antinociceptive interaction between WIN 55, 212-2, a cannabinoid agonist, and ketorolac. Anesth. Analg. 2006, 102:443-447.
79. Valverde O., Karsak M., Zimmer A. Analysis of the endocannabinoid system by using CB1 cannabinoid receptor knockout mice. Hand B. Exp. Pharmacol. 2005, 168:117-145.
80. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
81. Viscomi M.T., Oddi S., Latini L., Pasquariello N., Florenzano F., Bernardi G., Molinari M., Maccarrone M. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J. Neurosci. 2009, 29:4564-4570.
82. Walker J.M., Hohmann A.G. Cannabinoid mechanisms of pain suppression. Hand B Exp. Pharmacol. 2005, 168:509-554.
83. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 2006, 281:36569-36578.
84. Welch K.M. Contemporary concepts of migraine pathogenesis. Neurology 2003, 61:S2-S8.
85. Welch S.P. Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int. Rev. Psychiatry. 2009, 21:143-151.
86. Wotherspoon G., Fox A., McIntyre P., Colley S., Bevan S., Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005, 135:235-245.
87. Yates M.L., Barker E.L. Organized trafficking of anandamide and related lipids. Vitam. Horm. 2009, 81:25-53.
88. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl Acad. Sci. U. S. A. 1999, 96:5780-5785.